VCM
BMY.RT

Vigilant Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Vigilant Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-2,503
Closed -$2K – 394
2020
Q4 		$2K Hold
2,503
– – ﹤0.01% 328
2020
Q3 		$6K Buy
2,503
+800
+47% +$2.29K ﹤0.01% 327
2020
Q2 		$6K Hold
1,703
– – ﹤0.01% 297
2020
Q1 		$6K Hold
1,703
– – ﹤0.01% 307
2019
Q4 		$5K Buy
+1,703
New +$4.43K ﹤0.01% 449

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.82B AUM
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Vigilant Capital Management's BMY.RT Position: Q1 2021 in Review

Vigilant Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 2,503 shares — an estimated $2K sold.

Vigilant Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $6K in Q3 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Vigilant Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Vigilant Capital Management sold 2,503 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $2K.
  • Vigilant Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Vigilant Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $6K in Q3 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Vigilant Capital Management's 13F filing for Q1 2021, filed 16 Apr 2021.